AstraZeneca's Baxdrostat Shows Promising Results in Phase III Trial for Hard-to-Control Hypertension

AstraZeneca's Baxdrostat has shown statistically significant and clinically meaningful reduction in systolic blood pressure in patients with hard-to-control hypertension in the BaxHTN Phase III trial. The 2mg dose reduced systolic blood pressure by 15.7 mmHg and was well tolerated with no unexpected safety issues. Baxdrostat nearly tripled the odds of achieving a target systolic blood pressure of less than 130 mmHg compared to placebo.

AstraZeneca's Baxdrostat has shown statistically significant and clinically meaningful reductions in systolic blood pressure in patients with hard-to-control hypertension, as demonstrated in the BaxHTN Phase III trial. The 2mg dose of Baxdrostat lowered systolic blood pressure by 15.7 mmHg, with a placebo-adjusted reduction of 9.8 mmHg, according to data presented at the European Society of Cardiology Congress 2025 and published in the New England Journal of Medicine [1].

The trial, which enrolled 796 patients in a 1:1:1 ratio to receive Baxdrostat 2mg, 1mg, or placebo, found that both doses of Baxdrostat met the primary endpoint of reducing mean seated systolic blood pressure (SBP) at 12 weeks compared to placebo. The 1mg dose showed a placebo-adjusted reduction of 8.7 mmHg. The reduction in mean seated SBP with placebo was 5.8 mmHg [1].

Baxdrostat was generally well tolerated with no unanticipated safety findings. The safety profile was consistent with its mechanism of action, and most adverse events were mild. The trial also met all confirmatory secondary endpoints, including demonstrating durable long-term blood pressure reduction with Baxdrostat 2mg [1].

Both 2mg and 1mg doses of Baxdrostat nearly tripled the odds of patients achieving their target SBP of less than 130 mmHg compared to placebo. The trial also showed significant reductions in 24-hour and ambulatory nighttime SBP, key indicators of sustained blood pressure control and reduced cardiovascular risk [1].

Dr. Bryan Williams, Chair of Medicine at University College London and primary investigator, noted that the trial results underscore the importance of aldosterone in hard-to-control hypertension and the potential impact of Baxdrostat on millions of people living with the condition [1].

AstraZeneca plans to advance its regulatory filings for Baxdrostat with health authorities and progress its clinical development program across indications where aldosterone plays a key role, including chronic kidney disease and heart failure prevention [1].

References:
[1] https://www.tradingview.com/news/reuters.com,2025-08-30:newsml_Wkr3jVXBW:0-baxdrostat-demonstrated-statistically-significant-and-clinically-meaningful-reduction-in-systolic-blood-pressure-in-patients-with-hard-to-control-hypertension-in-the-baxhtn-phase-iii-trial/